Aethlon Medical, Inc. has announced that following recent exercises of certain pre-funded warrants, the company now has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026. This development indicates that all previously outstanding pre-funded warrants have been exercised, which may have implications for the company's capital structure and liquidity. The exercise of these warrants could potentially enhance the company's financial position by increasing the number of shares available for trading, thereby improving liquidity. However, it also results in dilution for existing shareholders, as the total number of shares outstanding has increased. The company is incorporated in Nevada and trades under the symbol AEMD on the Nasdaq Capital Market. The filing of this 8-K form serves to inform investors and stakeholders about the current status of the company's share structure and the implications of the warrant exercises.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.